Vocalbeats.AI Achieves ISO/IEC 42001 Certification, Reinforcing Responsible AI Governance Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors
REHOVOT, Israel and WILMINGTON, Del., Sept. 27, 2022 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq:…
Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors
REHOVOT, Israel and WILMINGTON, Del., Sept. 27, 2022 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq:…
Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors
REHOVOT, Israel and WILMINGTON, Del., Sept. 27, 2022 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq:…
PaxMedica, Inc. Provides Corporate Update After IPO
-PXMD Strengthened Executive Team with Recent Appointment of Stephen D. Sheldon As Chief Financial Officer-…
PaxMedica, Inc. Provides Corporate Update After IPO
-PXMD Strengthened Executive Team with Recent Appointment of Stephen D. Sheldon As Chief Financial Officer-…
PaxMedica, Inc. Provides Corporate Update After IPO
-PXMD Strengthened Executive Team with Recent Appointment of Stephen D. Sheldon As Chief Financial Officer-…
TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference
BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology…
TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference
BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology…
TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference
BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology…
Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
ORCA-3 Designed to Enable FDA Registration and Confirm the Efficacy and Safety of 3 mg…
Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
ORCA-3 Designed to Enable FDA Registration and Confirm the Efficacy and Safety of 3 mg…
Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
ORCA-3 Designed to Enable FDA Registration and Confirm the Efficacy and Safety of 3 mg…
Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical…
Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical…
Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical…
Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and…
Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and…
Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and…
BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives
VANCOUVER, British Columbia, Sept. 27, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives
VANCOUVER, British Columbia, Sept. 27, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…